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ABSTRACT
Objective: The aim of this paper is to evaluate 6‐year trends in community use of prescribed opioid analgesics in Albania, using the Anatomic 
Therapeutic Chemical Classification‐Defined Daily Dose methodology.
Methods: We collected the data from the database of the Health Insurance Institute (HII). Analysis of the data includes the period 2014–2019; also, 
we analyzed the data of import and domestic production of drugs, which represent the real consumption of drugs in the country. These data were 
subsequently involved in a comparative analysis of the utilization data according to the HII.
Results: We report a 2.5 fold increase in opioid utilization over the study period. The maximal rise in consumption refers to fentanyl, oxycodone, and 
tramadol. Meanwhile, the maximal values of consumption refer to strong opiate, morphine. We note that around 30% of the consumption of this class 
flows out of the scheme. Furthermore, around 25% of consumption of morphine and oxycodone flows out of scheme too. Meanwhile, the tramadol 
consumption runs out of the scheme over 200%.
Conclusions: The outcomes indicate that patients in Albania have low access to opioids medications mainly because of low opioids availability. 
A strong opiophobia among the population and the medical professionals constitutes one of the major impediments for efficient palliative care.
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INTRODUCTION
Opioids are a class of drugs naturally found in the opium poppy plant and 
that work in the brain to produce a variety of effects, including the relief 
of pain with many of these drugs. Some prescription opioids are a direct 
product of the plant. Other opioids are synthetized in labs, by using the 
same chemical structure. Opioids often are used as medicines because they 
contain chemicals that relax the body and can relieve pain. Opioids can also 
make people feel very relaxed and “high” ‐ which is why they are sometimes 
abused even for non‐medical reasons. This can be dangerous because 
opioids can be highly addictive, and overdoses and death are common.
The prevalence of chronic pain is high and affects 12–30% of all 
Europeans, with a considerable impact on self‐reported quality of life, 
posing a major international healthcare issue [1]. For some patients, 
opioids are used to treat chronic pain, and the total use of opioids more 
than doubled from 1999 to 2016 worldwide [2].
Prescription opioids might be used to treat moderate‐to‐severe pain. Often 
these are prescribed following surgery or injury, or for health conditions 
such as cancer. In recent years, there has been a dramatic increase in the 
acceptance and use of prescription opioids for the treatment of chronic 
non‐cancer pain (CNCP), such as back pain or osteoarthritis, despite 
serious risks and the lack of evidence about their long‐term effectiveness. 
Studies suggest that regional variation in use of prescription opioids 
cannot be explained by the underlying health status of the population [3]. 
More than 191 million opioid prescriptions were dispensed to American 
patients in 2017 ‐ with wide variation across states [4]. Anyone who 
takes prescription opioids can become addicted to them. In fact, as many 
as one in four patients receiving long‐term opioid therapy in a primary 
care setting struggles with opioid addiction [5‐7]. Once addicted, it can 
be hard to stop. In 2016, more than 11.5 million Americans reported 
misusing prescription opioids in the past year [4]. Taking too many 
prescription opioids could stop a person’s breathing ‐ leading to death.
In USA, Opioid prescriptions per capita increased 7.3% from 2007 
to 2012, with opioid prescribing rates increasing more for family 
practice, general practice, and internal medicine compared with other 
specialties [8]. Opioids are commonly prescribed for pain. An estimated 
20% of patients presenting to physician offices with non‐cancer pain 
symptoms or pain‐related diagnoses (including acute and chronic pain) 
receive an opioid prescription [9].
METHODS
The study aimed to assess the out‐of‐hospital Opioid drugs use in 
Albania during the period 2014–2019. The data were obtained from 
the Health Insurance Institute (HII) [10]. All data were collected for 
the period 2014–2019 and analyzed. The analysis included the total 
number of prescriptions made and quantities of drugs used.
The data about the population were obtained from the Institute of 
Statistics [11]. The data about the consumption of drugs were expressed 
as a number of Defined Daily Dose (DDDs)/1000 inhabitants/day. All 
drugs were classified by groups of Anatomic Therapeutic Chemical 
Classification (ATC).
Data on real consumption (import and domestic production)
For all the period under study 2014–2019, there were collected and 
analyzed data from the import and domestic production of the drugs, 
which represent the real consumption of drugs in the country [12]. 
To obtain an updated study, there were chosen the data of import and 
domestic consumption only for the last 4 years, 2016, 2017, 2018, 
and 2019 and those were involved in a comparative analysis with the 
equivalent consumption data according to HII. To minimize the effect 
of variations between consumption and stock inventory balances from 
1 year to another, it was calculated and put to analysis the annual 
average value of the three chosen years (on the one hand, that of the 
import and domestic consumption, and, on the other hand, that of HII).
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licenses/by/4.0/) DOI: http://dx.doi.org/10.22159/ajpcr.2021v14i11.42688. Journal homepage: https://innovareacademics.in/journals/index.php/ajpcr
Research Article
125
Asian J Pharm Clin Res, Vol 14, Issue 11, 2021, 124-128
 Kakariqi et al.
Presentation of the results and statistical elaboration
The database of HII was modified in Microsoft Office Excel 2007, whereas 
the statistical elaboration of the obtained results was conducted with the 
statistical package StatsDirect (version 2.7.2.). A descriptive statistic was 
used to report all data on drugs consumption and the results obtained 
were displayed in tabular form as well as through the histogram method.
Average annual values of consumption in the country level and for each 
district were used as a basis to generate the overviews and the graphics 
that illustrate the trends of consumption for each class of drugs during 
the 6‐years period 2014‐2019. The linear regression model was used to 
evaluate the trends of consumption of drugs relative to the time. A value 
of p≤0.05 was considered as significant.
RESULTS
The data are expressed as a number of DDDs per 1000 inhabitants/day 
(DDDs/1000 inhabitants/day).
The consumption of opioid drugs was 2.21–5.44 DDD/1000 inhabitants/day, 
respectively, in 2014–2019, reflecting a specific increase of approximately 
150%. The opioids included in the reimbursement scheme are morphine, 
fentanyl, oxycodone, pethidine, and tramadol. The most prescribed are 
morphine and oxycodone; meanwhile, the largest increase in consumption 
is attributed to fentanyl and oxycodone (Figs. 1 and 2) [13‐22].
DISCUSSION
Chronic pain is one of the largest contributors to global disability [23]. 
Prevention, assessment, and treatment of chronic pain are challenges for 
health providers and systems. Pain might go unrecognized, and patients, 
particularly members of racial and ethnic minority groups, women, the 
elderly, persons with cognitive impairment, and those with cancer and at 
the end of life, can be at risk for inadequate pain treatment [24]. Patients 
can experience persistent pain that is not well controlled. There are 
clinical, psychological, and social consequences associated with chronic 
pain including limitations in complex activities, lost work productivity, 
reduced quality of life, and stigma, emphasizing the importance of 
appropriate and compassionate patient care [24]. Chronic pain has been 
variably defined but is defined within this guideline as pain that typically 
lasts >3 months or past the time of normal tissue healing [25]. Chronic 
pain can be the result of an underlying medical disease or condition, 
injury, medical treatment, inflammation, or an unknown cause [24].
Evidence supports short‐term efficacy of opioids for reducing pain 
and improving function in non‐cancer nociceptive and neuropathic 
pain in randomized clinical trials lasting primarily ≤12 weeks [26,27], 
and patients receiving opioid therapy for chronic pain report some 
pain relief when surveyed [28‐30]. However, few studies have been 
conducted to rigorously assess the long‐term benefits of opioids for 
chronic pain (pain lasting >3 months) with outcomes examined at least 
1 year later [31]. Opioid pain medication use presents serious risks, 
including overdose and opioid use disorder. In the past decade, while 
the death rates for the top leading causes of death such as heart disease 
and cancer have decreased substantially, the death rate associated with 
opioid pain medication has increased markedly [32].
In the past two decades, various opioids, including oxycodone, 
hydromorphone, buprenorphine and fentanyl, have been registered 
and subsidized for the treatment of CNCP in many health care settings 
around the globe. These changes brought dramatic growth in opioid 
prescribing and use, despite uncertainty about their efficacy in the 
long‐term treatment of this indication [33,34].
This paper provides an evaluation of Albanian trends in prescribed opioid 
analgesic dispensing. Opioids are essential medicines for the treatment of 
pain and have been included in the 2007 Essential Medicines in Palliative 
Care by International Association for Hospice and Palliative Care. The list 
includes 34 medications of which 14 are already included in the WHO list as 
essential in the treatment of several conditions, some of which are common 
in palliative care from which 27 drugs or 75% are available in Albania. In 
the reimbursement drug list of Fund of Health Care Insurance, 17 drugs are 
included or 48%. Meanwhile, 20% of this group of drugs (reimbursed for 
palliative care) has limitations on their use and quantity [35].
We report a 2.5 fold increase in opioid utilization over the study period. 
The maximal rise in consumption refers to fentanyl, oxycodone, and 
tramadol. Meanwhile the maximal values of consumption refers to 
strong opiate (morphine), Figs. 1‐3 show clearly that consumption of 
opioids have an increasing trend, especially from 2016 onward.
Attempting to obtain a deeper understanding of what has really 
happened we included in the analysis the import data (which represent 
the real consumption), by comparing the average annual value of 
consumption of opioids drugs from imports with the equivalent value 
reported by the HII. Fig. 4 presents the comparison import‐HII in the 
consumption of opioids the whole class, and some representatives like 
morphine, tramadol, and oxycodone. We note that around 30% of the 
consumption of this class flows out of the scheme. Furthermore, around 
25% of consumption of morphine and oxycodone flows out of scheme 
too. Meanwhile, the tramadol consumption runs out of the scheme over 
200%. The distribution of opioids in the pharmaceutical market relies 
in accordance to a well‐determined regulation. Only a small number of 
pharmacies do have the right to sell opioids. These pharmacies apply 
for a special license with the Ministry of Health and Social Welfare. They 
can start selling opioids only after being equipped with such license and 
ensuring a separate place for opioids – a safe deposit box/cabinet. On the 
other hand, to have the right to purchase opioids, a patient should obtain 
a special medical prescription, duly signed and stamped by three doctors.
General physicians are able to prescribe opioids, but only after an oncological 
consultancy. The authority for prescribing opioids is limited to palliative 
Fig. 2: Opioid consumption at national level 
(Defined Daily Dose /1000 inhabitants/day) p=0.0089; strength 
(with significance level ≤0.05)=93.84%; correlation coefficient 
statistically significant
Fig. 1: Consumption of each opioid at national level (Defined Daily 
Dose /1000 inhabitants/day)
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care physicians and oncologists. There are four palliative care services 
operating in Albania. The length of a prescription has been limited to 7 days, 
but because of the new legal stipulations, it was expanded to a maximum of 
28 days [35]. For many years the only opiate available, was morphine 10 mg 
injection and 10 mg slow‐release tablet. In 2014, patch fentanyl was also 
included in the scheme. Whereas, in 2016, the scheme extended further by 
including morphine oral solution (oral drops) and oxycodone 10 mg tablet.
In Albania, prescription opioids are used almost entirely to treat cancer 
associated moderate‐to‐severe pain. They are prescribed in isolated 
cases also by an orthopedist or endocrinologist for the treatment of 
diabetic foot ulcer, or for pains from multiple fractures. On the contrary, 
in European countries opioids are commonly prescribed for pain. 
An estimated 20% of patients presenting to physician offices with 
non‐cancer pain symptoms or pain‐related diagnoses (including acute 
and chronic pain) receive an opioid prescription [9].
One reason for this prescription disparity is ophidiophobia, a closed 
mentality amongst the medical staff and throughout the population. 
Another possible reason may be their significantly high price in our 
country as compared to in other European countries. When comparing 
the scheme data with the customs import figures, where the latter indicate 
the real consumption in the country, we note that around 30% of opioids 
flow out of the scheme. We need to consider here that the customs import 
figures include also the hospital consumption of opioids. When analyzing 
item by item, we note consumption values out of the scheme at the level 
of 26% for morphine and 25% for oxycodone. An explanation for this 
finding may be the informal trading of these drugs (under the counter), 
or alternatively, their residual stock inventory may be an explanation. 
Between the two of them, oxycodone is more easily accessible.
Meanwhile, when we compare consumption values for tramadol, 
we note that the real consumption exceeds by far the consumption 
under the scheme, by around 3.4 times. Probable reasons are the fact 
that tramadol is available in all pharmacies, can be obtained through 
a simple prescription issued by only one doctor and its cost is much 
low. In fact it represents the only alternative in the opioids group that is 
prescribed extensively also in non‐cancer chronical pains.
The consumption of opioids undergoes an increasing trend more 
conspicuous from 2016 onwards (this year oxycodone and oral drops 
morphine solution were introduced to the reimbursement list). Minimum 
consumption is noted in Kukës throughout all years under study. High 
values of consumption for this class are noted in Tiranë and Durres. The first 
palliative care service provider in Albania, the Ryder Albanian Association 
(RAA) from 1993, operate precisely in Tirana and Durres. RAA’s focus is 
the provision of home care, palliative care, advocacy, and fundraising [35].
Worth mentioning is though that from 2015, in addition to the four 
nongovernment organizations providing palliative care, there are 
seven new palliative care units in the regional hospitals of Albania: In 
Shkodra, Elbasan, Durrës, Fieri, Berat, Korça, Kukësi, and Vlora offering 
inpatient and home care services for patients [35].
Comparisons of consumption at the international level
Opioids have become the cornerstone therapy for treatment of moderate 
to severe pain in many high‐income countries. For prescription opioids, 
while there is insufficient access in many low‐ and middle‐income 
countries, the reality in OECD countries is quite different, where the 
availability of analgesic opioids has been steadily growing. The United 
States has the highest availability of analgesic opioids among OECD 
countries, followed by Germany and Canada, while Mexico, Chile, and 
Colombia show the lowest numbers [36].
In 2019, we report dispensing of opioid analgesics at a rate of 
5.44 DDD/1000 inhabitants/day; this is much lower than rates 
in Canada (22 DDD/1000 inh/day in 2010) and Scandinavia 
(approximately 20 DDD/1000 inh/day in 2006), who are among 
the leading consumers of opioid analgesics globally. However, the 
use of opioids in the treatment of CNCP is controversial [37,38]. 
While randomized‐controlled trials have demonstrated efficacy of 
opioids for the short‐term treatment of chronic pain [39‐41], there is 
no high‐quality evidence for their long‐term efficacy [42‐44]. Other 
contributors to the increase in opioid utilization may include the 
ageing population; improvements in pain management and physician 
education; recognition of the serious side effects of NSAIDs and Cox‐2 
inhibitors; and growth in opioid misuse and diversion [45‐49]. In Fig. 5, 
we may again conclude that in Albania, these drugs are consumed a few 
times less as compared to the majority of other countries, leaving room 
Fig. 3: Consumption of opioids in different regions and at the national level (defined daily dose/1000 inhabitants/day)
Fig. 4: Annual average value of consumption of Opioids: 
Consumption based on import (real consumption) (*) versus 
Consumption based on Health Insurance Institute. (*) The 
“Import” item includes the consumption based on import data 
as well as the consumption based on domestic production: This 
represents the factual consumption 
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to assume that there is under‐treatment of pain disorder, and under 
provision of palliative care services throughout the country.
CONCLUSIONS
The outcomes indicate that patients in Albania have low access to 
opioids medication, mainly because of low opioids availability. A strong 
opiophobia among the population and the medical professionals 
constitutes one of the major impediments for efficient palliative care. 
To remove this barrier to the treatment of pain, there is a need for a 
better awareness and education of clinicians, so to avoid exaggerated 
fear from side effects or addiction, while using this highly efficacious 
pain‐relieving type of medication.
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